Related Experiment Video
Updated: Jan 14, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Therapeutic targets of corn silk polysaccharide on hypoglycemic effect and mechanisms: Experimental validation of
Zhang Lei1, Yang Yue1, Li Xiaoyu1
1College of Life Science and Technology, Mudanjiang Normal University, Mudanjiang, China.
Abstract:
We investigated the hypoglycemic effect and mechanism of corn silk polysaccharide in diabetic mice. Through network pharmacology, we found that corn silk polysaccharides exerted hypoglycemic effects through 104 therapeutic diabetic targets, MAPK and dopaminergic synaptic signaling pathways. Molecular docking experiments showed that the core target SRC had the best binding activity to D-Mannose, with a binding energy of -6.012 KJ/mol. In-vivo experiments demonstrated that corn silk polysaccharide reduced blood glucose level, glucose tolerance and improved body weight disorders in T2DM mice (P<0.01). In addition, corn silk polysaccharide can promote the recovery of pancreatic islet cell morphology in T2DM mice and the recovery effect was more obvious in large doses of corn silk polysaccharide. This suggests that corn silk polysaccharide can treat type 2 diabetes mellitus through multi-targets and multiple pathways. Meanwhile, corn silk polysaccharide extract had positive effects on blood glucose, body weight disorder and glucose tolerance in T2DM mice, which might be accomplished by restoring the morphology of pancreatic islet cells.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones